Napredna pretraga

Pregled bibliografske jedinice broj: 1014288

Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients

Sušac, Ilona; Ozretić, Petar; Gregorić, Maja; Levačić Cvok, Mirela; Sabol, Maja; Levanat, Sonja; Trnski, Diana; Eljuga, Domagoj; Seiwerth, Sven; Aralica, Gorana et al.
Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients // Journal of Oncology, 2019 (2019), 3483192, 10 doi:10.1155/2019/3483192 (međunarodna recenzija, članak, znanstveni)

Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients

Sušac, Ilona ; Ozretić, Petar ; Gregorić, Maja ; Levačić Cvok, Mirela ; Sabol, Maja ; Levanat, Sonja ; Trnski, Diana ; Eljuga, Domagoj ; Seiwerth, Sven ; Aralica, Gorana ; Stanec, Mladen ; Musani, Vesna

Journal of Oncology (1687-8450) 2019 (2019); 3483192, 10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
BIRC5 ; survivin ; polymorphisms ; breast cancer ; IHC

Survivin, encoded by BIRC5 gene (baculoviral IAP repeat containing 5), belongs to the family of inhibitors of apoptosis proteins (IAPs). In mammalian cells it participates in the control of mitosis, apoptosis regulation, and cellular stress response. Its expression is increased in almost all types of cancers. The aim of this study was to investigate the role of BIRC5 polymorphisms in breast cancer (BC) and to connect survivin expression with various clinicopathological characteristics of BC patients. Blood and archival tumour tissue samples were collected from 26 BC patients from Croatia. Survivin expression was determined immunohistochemically. BIRC5 promoter, coding region, and 3’UTR were genotyped. DNA from 74 healthy women was used as control. BIRC5 polymorphisms and survivin expression were tested against age of onset, histological grade, tumour type and size, lymph node status, oestrogen, progesterone, Her2, and Ki67 status. Numbers of samples with weak, moderate, and strong survivin expression were 9 (33.3%), 11 (40.7%), and 7 (25.9%), respectively. Most patients had nuclear survivin staining (92.6%). High survivin expression was significantly associated with negative oestrogen receptor status (p=0.007) and positive Ki67 expression (p=0.032). Ki67 expression was also positively correlated with histological grade (p=0.0009). Fourteen polymorphisms were found in BC samples, located mostly in promoter and 3’UTR of BIRC5. There was no significant difference in the distribution of polymorphisms between BC and control samples. Among clinicopathological characteristics of BC patients, alleles of five BIRC5 polymorphisms were associated with younger age of onset: c.-644T>C (55.8 years [y] vs. 48.1 y ; p=0.006), c.-241C>T (54.2 y vs. 45.0 ; p=0.029), c.9809T>C (55.8 y vs. 48.1 y ; p=0.006), c.-1547C>T (58.3 y vs. 50.9 y ; p=0.011), and c.9386T>C (50.8 y vs. 59.5 y ; p=0.004). To assess the significance of BIRC5 polymorphisms and survivin expression as predictive and prognostic biomarkers for BC further research with a larger sample size is needed.

Izvorni jezik

Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti


Klinika za tumore,
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb

Časopis indeksira:

  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
    • Emerging Sources Citation Index (ESCI)
  • Scopus

Uključenost u ostale bibliografske baze podataka:

  • Biological Sciences
  • EMBASE (Excerpta Medica)
  • Oncogenes and Growth Factors Abstracts